MEQUON, Wis., July 7, 2026
Vector Science & Therapeutics Corp. has entered into a landmark exclusive licensing and cGMP manufacturing agreement with LyoGenesis Plus, strengthening its commercial strategy for a broad portfolio of pharmaceutical-grade peptide therapeutics. The strategic collaboration combines Vector’s proprietary biomechanical peptide delivery platform with LyoGenesis’ cGMP manufacturing and lyophilization expertise, creating an integrated development and manufacturing model designed to accelerate commercialization while ensuring pharmaceutical-quality production standards. The agreement replaces Vector’s previously announced investment option in LyoGenesis with a direct commercial partnership under which Vector licenses its patented delivery technology while securing an exclusive long-term manufacturing relationship for its proprietary peptide portfolio. All products will be manufactured at LyoGenesis’ cGMP-compliant facility in Mequon, Wisconsin, where every batch will undergo rigorous analytical testing for potency, purity, sterility, endotoxin levels, and heavy metals before release. The partnership supports Vector’s objective of delivering high-quality peptide therapies exclusively through physician and clinical channels, reinforcing compliance with pharmaceutical manufacturing standards while expanding production capacity to meet growing global demand.
Exclusive cGMP Manufacturing Strengthens Commercial Strategy
The collaboration establishes a long-term manufacturing infrastructure capable of supporting the commercialization of Vector’s expanding peptide therapeutics portfolio, which includes numerous proprietary and clinically relevant peptide candidates targeting metabolic disorders, regenerative medicine, sports medicine, endocrinology, and other therapeutic applications. Through the agreement, LyoGenesis Plus will further develop Vector’s patented delivery platform while optimizing manufacturing processes to support commercial-scale production. The facility is expected to scale production to as many as 800,000 pharmaceutical-grade peptide vials per month, providing the manufacturing capacity needed to support future market expansion.
According to Tom Bachinski, Chief Technology Officer of Vector Science & Therapeutics, the agreement enables the company to transition from scientific innovation to commercial manufacturing without compromising product quality, supply security, or regulatory compliance. The partnership also allows Vector to retain strategic control over its proprietary technologies while leveraging LyoGenesis’ specialized expertise in cGMP manufacturing and lyophilization.
Peptide Platform Supports Growing Pharmaceutical Market
Advertisement
Vector’s proprietary biomechanical peptide delivery platform utilizes nanoscale carrier technology designed to deliver peptides directly to targeted tissue sites, enabling localized therapeutic release while differentiating the company’s products from conventional peptide formulations. The company’s expanding peptide portfolio includes several well-known peptide candidates such as Semaglutide, Tirzepatide, Sermorelin, Ipamorelin, MOTS-c, BPC-157, TB-500, PT-141, GHK-Cu, and other investigational compounds intended for physician-supervised therapeutic use. As global demand for peptide-based medicines continues to accelerate, particularly in metabolic disease, obesity, oncology, and regenerative medicine, the strategic manufacturing partnership positions Vector to support future commercialization through a reliable, scalable, and quality-controlled pharmaceutical supply chain.
The agreement also strengthens the company’s Valor sports medicine division while reinforcing its long-term commitment to delivering patent-protected peptide therapeutics manufactured under stringent current Good Manufacturing Practice (cGMP) standards. By combining innovative drug delivery technology with dedicated manufacturing infrastructure, Vector Science & Therapeutics is establishing a comprehensive platform capable of supporting future clinical and commercial growth while addressing increasing physician demand for pharmaceutical-grade peptide therapies produced under rigorous regulatory and quality standards.
Source: Vector Science & Therapeutics press release
